Company intelligence / Profile preview

Guilin Pavay Gene Pharmaceutical

Guilin, Guangxi Zhuang Autonomous Region, Chinaen.guilinpharma.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed and commercialized two recombinant human epidermal growth factor-based biopharmaceuticals—one for skin wound healing and one as an eye drop for corneal diseases. Both products have been approved as State category one new bio-pharmaceutical medicines by the Chinese regulator. Clinical studies support their efficacy in wound healing and ophthalmic indications, with the eye drop product approved since at least April 2002.[1][5]

Therapeutic areas: DermatologyOphthalmology
Modalities: Protein (Growth factor)Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Guilin Pavay Gene Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guilin Pavay Gene Pharmaceutical.

Explore the full profile